OS THERAPIES INCORPORATED (NYSE: OSTX)

OS THERAPIES INCORPORATED

NYSE: OSTX (OS Therapies Incorporated)

Last update: 5 days ago, 10:34PM

1.20

-0.06 (-4.76%)

Add to watchlist

Previous Close	1.26
Open	1.25
Volume	812,953
Avg. Volume (3M)	538,970
Market Cap	42,257,224

Price / Book

13.46

52 Weeks Range	1.12 (-6%) — 2.98 (148%)
Earnings Date	17 Nov 2025

Market Trend

		Short Term	Medium Term
Industry	Biotechnology (US)	Bullish	Mixed
	Biotechnology (Global)	Bullish	Mixed
Stock	OS Therapies Incorporated	-	-

AIStockmoo Score

0.6

Analyst Consensus	2.0
Insider Activity	NA
Price Volatility	3.0
Technical Moving Averages	0.0
Technical Oscillators	-2.5
Average	0.63

Similar Stocks

Stock	Market Cap	DY	P/E (TTM)	P/B
OSTX	42 M	-	-	13.46
LCTX	387 M	-	-	17.45
CYBN	359 M	-	-	2.70
PLX	235 M	-	32.44	4.10
ARMP	233 M	-	-	2.11
IBIO	45 M	-	-	1.32

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.
Sector	Healthcare
Industry	Biotechnology
% Held by Insiders	33.38%
% Held by Institutions	1.38%

Ownership

Name	Date	Shares Held
Cm Management, Llc	31 Dec 2025	400,000
Mercer Global Advisors Inc /Adv	30 Sep 2025	20,440

No data within this time range.

Date	Type	Details
04 Feb 2026	Announcement	OS Therapies Applauds Reauthorization of Pediatric Priority Review Voucher Program to Advance Breakthrough Osteosarcoma Immunotherapies
02 Feb 2026	Announcement	OS Therapies Initiates US FDA BLA Filing for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
15 Jan 2026	Announcement	OS Therapies Announces Positive Biomarker Data from Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
14 Jan 2026	Announcement	OS Therapies Announces Filing Form S-1 of OS Animal Health Subsidiary
12 Jan 2026	Announcement	OS Therapies Enters into Warrant Inducement Agreements
05 Jan 2026	Announcement	OS Therapies Provides First Half 2026 Corporate Outlook
15 Dec 2025	Announcement	OS Therapies Announces Successful Type C Meeting with US FDA Regarding Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
09 Dec 2025	Announcement	OS Therapies Announces Successful pre-Marketing Authorisation Application Meeting with UK MHRA Regarding the Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
05 Dec 2025	Announcement	OS Therapies Announces FDA PDUFA Waiver & EMA Grants Union Marketing Authorisation Eligibility
25 Nov 2025	Announcement	OS Therapies Receives Non-Proprietary Name 'daznelimgene lisbac' for OST-HER2 from World Health Organization
21 Nov 2025	Announcement	Stonegate Capital Partners Updates Coverage on OS Therapies Inc. (OSTX) 3Q25
20 Nov 2025	Announcement	OS Therapies to Spinoff OS Animal Health into Standalone Public Company
17 Nov 2025	Announcement	OS Therapies Reports Third Quarter 2025 Financial Results and Provides Business Update
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

Realized Profit	-
Unrealized Profit	-
Dividend Received 2026	-
Total Profit	-
Avg. Return	-
Quantity (Buy)	-
Avg. Price (Buy)	-
Quantity (Sold)	-
Avg. Price (Sold)	-

No stocks matching your criteria

Current Ratio (MRQ)	1.16
Operating Cash Flow (TTM)	-10.08 M
Levered Free Cash Flow (TTM)	-12.28 M

Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)